XOMA Royalty (LTS:0M26) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M26 XOMA Royalty Corp LTS:0M26
35 GF Score
Price $40.89
GF Value $18.92
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0M26
35GF Score
XOMA Royalty Corp LTS:0M26
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XOMA Royalty (LTS:0M26) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $40.89 is trading 116.1% above its estimated GF Value™ of $18.92. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for LTS:0M26:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $18.92 vs. price of $40.89 (116.1% above fair value)
  • GF Score™: 35/100 with 9 warning signs

No single metric tells the full story. See the LTS:0M26 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
35GF Score

Get the complete analysis for LTS:0M26

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.89
Price
$18.92
GF Value